(NASDAQ: CNTB) Connect Biopharma Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 103.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Connect Biopharma Holdings's revenue in 2025 is N/A.On average, 6 Wall Street analysts forecast CNTB's revenue for 2025 to be $10,822,697, with the lowest CNTB revenue forecast at $0, and the highest CNTB revenue forecast at $41,746,507. On average, 5 Wall Street analysts forecast CNTB's revenue for 2026 to be $4,154,749,086, with the lowest CNTB revenue forecast at $38,963,407, and the highest CNTB revenue forecast at $8,511,868,889.
In 2027, CNTB is forecast to generate $7,152,295,453 in revenue, with the lowest revenue forecast at $38,963,407 and the highest revenue forecast at $14,683,616,725.